Discover breakthroughs in cardiac health and how they could change future treatments. Hear the latest insights in gene editing, RNA interference therapies, and digital health from the experts leading the studies.
Join Richmond Pharmacology, University College of London, and Richmond Research Institute as we share our learnings and answer questions.
Professor Julian Gillmore from University College London’s National Amyloidosis Centre presents findings from the ground breaking first-in-human study with NTLA-2001, sponsored by Intellia Therapeutics and Regeneron Pharmaceuticals.
NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) system and comprises a lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting TTR.
Learn how this Nobel-prize winning gene-editing technology could revolutionise the treatment of hereditary transthyretin (ATTR) amyloidosis.
Hypertension is a leading cause of mortality and morbidity worldwide. Despite effective antihypertensives, hypertension is uncontrolled in around 50% of patients and over 50% of patients do not take the medication as prescribed. ALN-AGT, an RNA interference therapeutic targeting hepatic angiotensinogen synthesis in hypertensive patients, is designed to be administered two times a year by sub-cutaneous injection – a more favourable treatment method for patients than daily tablets.
Dr Jorg Taubel, from Richmond Pharmacology presents insights from a cutting edge First-In-Human Trial for hypertension. The phase 1 trial conducted at Richmond Pharmacology demonstrated favourable results with reductions in circulating angiotensinogen and blood pressure after six months.
Dr Domenic Pimenta from Richmond Research Institute explains the community clinical trial that supported amyloidosis patients throughout the pandemic and how this is being extended using the PATHWAY-RCT trial to build on the successes.
Cardiac amyloidosis is a high-risk heart failure condition, with up to 60% of patients admitted to hospital annually. Coupled with the pandemic limiting access to care, this compounded patient need. In response, Richmond Pharmacology set up home telemonitoring to counter these new gaps in the community. Building on these successes RRI is about to start PATHWAY-RCT (preventing admission to hospital in ATTR cardiomyopathy using remote cardiac telemonitoring) - a community clinical trial of telemonitoring in cardiac amyloidosis. Here we present our set up, protocols and discuss the other novel technologies we might use to shift the paradigm in cardiac amyloidosis care.
This face-to-face event is free to attend but places are limited to ensure social distancing. To register, email email@example.com.
We ask all attendees to have a lateral flow test on arrival to safeguard all participants.
8th December 2021, Glaziers Hall, 9 Montague Cl, London SE1 9DD
Your comfort and safety are our top priority so we will ensure social distancing is possible throughout the event and encourage all participants to wear a mask.
All delegates will need to show their vaccine passport and have a negative lateral flow test on arrival.
Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.
We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.